European SCA3 project

The European SCA3 project is a multi-centre European project which is coordinated at the German Centre for neurodegenerative diseases in Bonn. This project has received funding of 1.6M euros from the EU Joint Programme for Neurodegenerative Disease Research as a...

Europees SCA3 project

Spinocerebellaire ataxie type 3 (SCA3) is een dominant erfelijke ziekte van de kleine hersenen, die met name gepaard gaat met loop- en evenwichtsproblemen, vallen, trillen van de handen, spraak- en slikproblemen, en moeite met het besturen van de ogen. De klachten...

Biohaven – Negative data in SCA trial

Press release October 2, 2017Biohaven reports that the efficacy of trigriluzole could not be proved in a 8 week trial.Trigriluzole, a novel glutamate modulator, is a drug candidate being developed by Biohaven as a potential treatment for patients with SCA.The study is...